Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04950114 · ClinicalTrials.gov registry record · Phase 2
An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases
A Phase 2 study, sponsored by Goldfinch Bio.
- Terminated
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT04950114: Clinical Trial Phase 2 study, sponsored by Goldfinch Bio.
NCT04950114 is a Phase 2 study that was terminated before completion, run by Goldfinch Bio. The registered enrollment target is 31 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04950114, a Phase 2 study, was terminated before completion, sponsored by Goldfinch Bio.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
This is an open-label Phase 2 study evaluating the long term safety and tolerability of GFB-887 in patients with focal segmental glomerulosclerosis (FSGS), and treatment-resistant minimal change disease (TR-MCD)
Primary Outcome
Incidence and severity of adverse events
Interventions
- DRUG GFB-887
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2021-07-27 |
| Est. Completion | 2022-11-02 |
| Phase | Phase 2 |
Why NCT04950114 stopped before completion
NCT04950114 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 1 intervention - of which GFB-887 is the first listed.
NCT04950114 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04950114 about?
NCT04950114 is a clinical study titled "An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases". This is an open-label Phase 2 study evaluating the long term safety and tolerability of GFB-887 in patients with focal segmental glomerulosclerosis (FSGS), and treatment-resistant minimal change disease (TR-MCD)
What is the current status of trial NCT04950114?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2021-07-27. Estimated completion is 2022-11-02.
What interventions are being tested in trial NCT04950114?
The interventions under investigation include: GFB-887 (DRUG).
Who is sponsoring clinical trial NCT04950114?
This trial is sponsored by Goldfinch Bio, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04950114's enrollment target sits among peer trials
31 1578th of 2000 higher than 419 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI